---
layout: post
title: "Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution"
date: 2026-02-05 19:01:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-26057
original_published: 2022-11-30 00:00:00 +0000
significance: 8.00
---

# Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 30, 2022 00:00 UTC
**Document Number:** 2022-26057

## Summary

The Food and Drug Administration (FDA) is withdrawing approval of new drug application (NDA) 019832 for SULFAMYLON[supreg] (Mafenide Acetate, USP) Powder for 5% Topical Solution, held by Mylan Institutional, Inc., a Viatris company (Mylan). Mylan has voluntarily requested withdrawal of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/30/2022-26057/mylan-institutional-inc-withdrawal-of-approval-of-a-new-drug-application-for-sulfamylon-mafenide)
- API: https://www.federalregister.gov/api/v1/documents/2022-26057

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
